All In Biotech

Drug Trial Radar · NCT06998771

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

A Phase II Trial to Evaluate the Safety and Efficacy of JSKN003 Combination Therapy as First-line Treatment in HER2-positive Unresectable Locally Advanced or Metastatic Gastric Cancer or Resectable Gastric Cancer

Last checked: Nov 19, 2026Latest source record: May 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 153 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

153

Planned (sponsor's estimate)

Start

Jun 15, 2025

Primary completion

Jun 30, 2028

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
May 31, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the safety and efficacy of JSKN003 combination therapy as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer or resectable gastric cancer.

Conditions

  • HER2-positive Gastric Cancer

Interventions

  • JSKN003Drug

    JSKN003 is administered by intravenous infusion.

  • KN026Drug

    KN026 is administered by intravenous infusion.

  • CapecitabineDrug

    Capecitabine is for oral administration.

  • EnlonstobartDrug

    Enlonstobart is administered by intravenous infusion.

  • OxaliplatinDrug

    Oxaliplatin is administered by intravenous infusion.

  • TrastuzumabDrug

    Trastuzumab is administered by intravenous infusion.

  • PembolizumabDrug

    Pembolizumab is administered by intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) of the first-line populationTime frame: Frame: Up to approximately 5 years
  2. Incidence and severity of TEAE and SAE of the first-line populationTime frame: Up to approximately 5 years
  3. pCR rate after neoadjuvant therapy of perioperative populationTime frame: Up to approximately 5 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.